RHS Limited, formerly Reproductive Health Science Limited, is engaged in the product development and commercialization of biotechnology technologies. Its principal activities include the development and marketing of its biotechnology technologies, including its products, EmbryoCellect for Preimplantation Genetic Screening (PGS) and DOPlify Whole Genome Amplification kit (WGA). EmbryoCellect uses microarray technology (array Comparative Genomic Hybridization) to compare the number of chromosomes in a sample cell to a known reference sample. The samples are labelled with various fluorescent dyes and the amount of fluorescence is measured and compared for each chromosome. It helps in counting the number of chromosomes in the test cell. DOPlify captures know-how for the lysis and whole genome amplification of single or small numbers of cells providing a solution for multiplying the limited deoxyribonucleic acid in a single cell for a range of downstream applications.